A gestational diabetes diagnosis during pregnancy brings a lot of new information to absorb quickly, including glucose monitoring requirements that are more frequent and more stringent than what most people have ever needed before. For many expecting mothers, the question of whether a CGM could make that monitoring easier and more effective is a reasonable one to ask. The answer depends on your specific situation, your type of diabetes, and how your care is structured, but the research behind CGM in pregnancy has grown significantly in recent years and is worth understanding. This guide covers what CGM can and cannot do during pregnancy, what the current evidence shows, and what expecting mothers with gestational or preexisting diabetes should know before making a decision.
Glucose Monitoring During Pregnancy: What Changes and Why
Glucose targets during pregnancy are tighter than at any other time in diabetes management. According to a clinical review published in PubMed Central in Diabetes Spectrum, the pregnancy-specific time in range target (known as TIRp) is defined as glucose between 63 and 140 mg/dL, compared to the standard non-pregnancy target of 70 to 180 mg/dL. The goal during pregnancy is to spend at least 70% of the day within this tighter range. Research shows that every additional 5% of TIRp is associated with reduced risk of complications for both the mother and baby.
Here's why those tighter targets matter:
- Large for gestational age (LGA) babies: Elevated maternal glucose crosses the placenta and can cause excessive fetal growth, leading to delivery complications and a higher risk of neonatal hypoglycemia
- Neonatal hypoglycemia: Babies born to mothers with poorly controlled glucose may produce excess insulin in response to high in-utero glucose, causing dangerously low blood sugar after birth
- Preeclampsia: Higher glucose variability in pregnancy is associated with increased risk of hypertensive complications
- Cesarean delivery: Larger birth size related to poor glucose control is a leading driver of unplanned C-sections
Traditional self-monitoring of blood glucose (SMBG) with a fingerstick meter requires checking four to eight times per day during pregnancy to capture fasting, post-meal, and overnight values. CGM offers continuous visibility into these patterns without the manual testing burden, which is part of why its role in pregnancy management is expanding.
What the Research Shows About CGM During Pregnancy
The evidence supporting CGM use in pregnancy has been growing, particularly for people with type 1 diabetes, and increasingly for those with gestational diabetes and type 2 diabetes as well.
A comprehensive review published in PubMed Central examined CGM use across pregestational type 1 and type 2 diabetes and gestational diabetes mellitus. The review found that CGM can reduce glucose fluctuations and the occurrence of serious hypoglycemia and hyperglycemia events in pregnant patients, and that higher TIR during pregnancy is consistently associated with better neonatal outcomes. One study cited in the review found that CGM use was associated with reduced rates of LGA babies (53% versus 69% in the standard care group) and a significant reduction in neonatal hypoglycemia requiring intravenous dextrose (15% versus 28%).
For people with type 1 diabetes specifically, the benefits are the most clearly established. CGM is now broadly recommended for pregnant individuals with type 1 diabetes by major diabetes organizations because of strong evidence linking CGM use to improved A1C and reduced neonatal complications. A real-world Swedish study of 186 pregnant women with type 1 diabetes found that time in range improved from 50% in the first trimester to 60% in the third trimester, and that users of real-time CGM spent significantly less time in hypoglycemia than those using intermittently scanned CGM, largely because real-time devices provide proactive low alerts without requiring a scan.
For gestational diabetes specifically, the evidence is more mixed. Some studies have shown meaningful improvements in outcomes with CGM use in GDM, including reduced birth weight and macrosomia rates, while others have found no statistically significant difference. The current clinical consensus, reflected in guidelines from the ADA and other organizations, is that CGM is most clearly indicated for pregnant people with preexisting type 1 or type 2 diabetes and for those with GDM on insulin therapy or experiencing significant glucose variability.
Which CGMs Are Approved for Use During Pregnancy
Not all CGMs carry FDA approval for use during pregnancy, and this is an important distinction for expecting mothers to understand before selecting a device.
Among the CGMs available through Adapt Health Diabetes, the FreeStyle Libre 3 Plus and FreeStyle Libre 2 Plus are both approved for use during pregnancy, according to the ADA Consumer Guide. The Dexcom G7 is also listed as pregnancy-approved. The Medtronic Guardian 4 sensor is not approved for use during pregnancy.
The practical difference between these devices in a pregnancy context comes down to alert capability. The FreeStyle Libre 2 Plus and Libre 3 Plus both offer real-time optional alerts for high and low glucose, which can help catch overnight lows, a particular concern in pregnancy when symptom awareness may be reduced during sleep. The Libre 3 Plus also transmits data automatically every minute without requiring a scan, which provides more seamless overnight monitoring.
The Dexcom G7's predictive Urgent Low Soon alert, which activates up to 20 minutes before a projected severe low, is a feature some maternal-fetal medicine providers consider particularly valuable for pregnant patients with type 1 diabetes and hypoglycemia unawareness.
Regardless of which device you use, review your specific CGM manufacturer's accuracy data and indication details with your OB or maternal-fetal medicine specialist. The pregnancy-specific time in range target of 63 to 140 mg/dL is tighter than many CGM alert default settings, so your care team will likely need to adjust your alert thresholds to align with pregnancy-specific goals.
Why Glucose Visibility Matters More During Pregnancy Than at Any Other Time
During pregnancy, the stakes of glucose management are higher and the windows for action are narrower than at almost any other point in a person's life with diabetes. Post-meal glucose spikes that might be manageable in a non-pregnant context can have consequences for fetal growth and development when they happen repeatedly across months of gestation. A CGM doesn't replace the work of careful management, but it gives you and your care team far more information to act on than a handful of daily fingerstick checks. For expecting mothers managing preexisting type 1 or type 2 diabetes, CGM has become an important standard of care. For those managing gestational diabetes with insulin, it is increasingly being incorporated into clinical practice as evidence grows. Speak with your OB or endocrinologist about whether a CGM is right for your situation, and visit our Learning Center and Education page for more resources on CGM use and diabetes management.
Frequently Asked Questions About CGM and Gestational Diabetes
Does insurance cover a CGM for gestational diabetes?
Coverage for CGM in gestational diabetes varies more than coverage for type 1 or type 2 diabetes with insulin use. Many private insurance plans and Medicaid programs cover CGMs for GDM patients who are on insulin therapy, as the clinical need for frequent monitoring is well-established in that context. Coverage for diet-controlled or non-insulin GDM is less consistent. Medicare generally does not apply to gestational diabetes since GDM affects pregnant individuals who are typically not Medicare-eligible. If you have gestational diabetes and are interested in a CGM, having your OB or endocrinologist document the clinical need as part of a prior authorization request gives you the strongest pathway to approval.
Are the glucose targets different for gestational diabetes compared to regular diabetes?
Yes, significantly. The pregnancy-specific time in range target (TIRp) uses a tighter glucose range of 63 to 140 mg/dL, compared to the standard non-pregnancy range of 70 to 180 mg/dL. The goal is to spend at least 70% of the day within that pregnancy-specific range. Post-meal glucose targets during pregnancy are also tighter than standard targets, with most guidelines recommending glucose below 120 to 130 mg/dL one to two hours after a meal. Your OB or maternal-fetal medicine specialist will establish personalized targets based on your situation, but expecting these to be more demanding than your pre-pregnancy targets is important to know going in.
Can I use an insulin pump during pregnancy if I have gestational diabetes?
Insulin pumps are most commonly used during pregnancy by people who have been on pump therapy before conception with preexisting type 1 or type 2 diabetes, rather than people newly diagnosed with GDM. That said, some people with GDM requiring insulin do use pump therapy if their clinical situation supports it. CGM-integrated AID systems approved for use during pregnancy are more limited, as many automated delivery systems are not currently indicated for pregnancy. Discuss your insulin delivery options with your OB and endocrinologist, as the decision depends on your glucose patterns, insulin requirements, and clinical history.
Will gestational diabetes go away after I deliver?
For most people, gestational diabetes resolves after delivery once the placental hormones that drove insulin resistance are no longer present. However, having GDM significantly increases the lifetime risk of developing type 2 diabetes. The American Diabetes Association recommends that people who had GDM be tested for type 2 diabetes or prediabetes at six to twelve weeks postpartum and regularly thereafter. In the postpartum period, glucose monitoring needs change significantly and your care team will guide you through what monitoring is appropriate.
How often does a CGM need to be replaced during pregnancy?
Sensor wear times are the same during pregnancy as at any other time: 14 to 15 days for FreeStyle Libre sensors and 10 days for the Dexcom G7. The pregnancy-approved FreeStyle Libre 3 Plus offers a 15-day wear period, and the Libre 2 Plus offers up to 15 days as well. Sensor replacement frequency is not affected by pregnancy itself, though some women find that skin changes during pregnancy, including increased sensitivity or skin texture changes, affect adhesion. The same adhesion strategies that work for non-pregnant users, including skin prep wipes and over-patches, apply equally well during pregnancy.
Get Your Pregnancy-Approved CGM Supplies Through Your Insurance
Adapt Health Diabetes carries pregnancy-approved CGM sensors for both the Abbott FreeStyle Libre and Dexcom G7 lines, verified through your insurance and delivered to your door. Visit our Resources page for more support, or contact our team with questions about coverage for your specific situation.
This article is for educational purposes only and does not replace professional medical advice. All glucose monitoring and management decisions during pregnancy should be made in close collaboration with your OB, maternal-fetal medicine specialist, and diabetes care team.
Sources
- Murphy HR. Roadmap to the Effective Use of Continuous Glucose Monitoring in Pregnancy. Diabetes Spectrum / PubMed Central. 2023.
- Martínez-Barona S, et al. The Benefits of Continuous Glucose Monitoring in Pregnancy. PubMed Central. 2023.
- Chen L, et al. Progress and Indication for Use of Continuous Glucose Monitoring in Patients with Diabetes in Pregnancy: A Review. PubMed Central. 2023.
- American Diabetes Association. FreeStyle Libre 3 and FreeStyle Libre 3 Plus. ADA Consumer Guide.
